High-Dose Vitamin D and Multiple Sclerosis: Promising Results from a Gold-Standard Clinical Trial
In a recent MedCram update, Dr. Roger Seheult breaks down a landmark study exploring the effects of high-dose vitamin D on patients with early-stage multiple sclerosis (MS). This multicenter, double-blinded, randomized controlled trial—the gold standard in clinical research—offers new insights into how vitamin D may impact disease progression.
What Is Multiple Sclerosis?
Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, causing inflammation, demyelination (loss of the protective covering of nerves), and neurological symptoms. Diagnosing MS often includes brain imaging (MRI), detection of oligoclonal bands in spinal fluid, and identifying clinical signs of a clinically isolated syndrome (CIS)—the first episode suggestive of MS.
The Trial: Key Details
-
Published: March 10, 2025, in JAMA Network
-
Participants: 316 patients ages 18–55 with CIS and low vitamin D levels (<40 ng/mL)
-
Design:
-
Double-blind
-
Placebo-controlled
-
Randomized
-
Multicenter (conducted across several clinical sites)
-
-
Intervention: 100,000 IU of oral vitamin D every 2 weeks for 2 years
-
Control: Placebo group with identical-looking treatment
Results: Reduced New Lesions on MRI
-
Intervention group (Vitamin D):
-
94 patients (60.3%) showed new lesions on MRI
-
-
Placebo group:
-
109 patients (74.1%) had new lesions
-
-
Relative Risk Reduction: ~18.6%
-
Absolute Risk Reduction: 13.8%
-
Number Needed to Treat (NNT): 8
→ For every 8 patients treated with high-dose vitamin D for 2 years, one recurrence was prevented.
These results were statistically significant (P = 0.004) and point to a meaningful reduction in disease activity as detected on imaging.
What About Clinical Outcomes?
The study also looked at 10 clinical endpoints (e.g., physical symptoms, disease progression), but no statistically significant differences were found between the vitamin D and placebo groups in these measures. While the vitamin D group had fewer clinical relapses numerically, the findings did not reach statistical significance.
Beyond Supplements: The Role of Sunlight
Dr. Seheult emphasized that while vitamin D is beneficial, sunlight exposure may offer additional neuroprotective effects not solely explained by vitamin D levels. Previous studies have shown that:
-
Sunlight exposure increases gray matter volume in the brain.
-
Latitude (how far north or south you live) influences MS risk—lower sunlight exposure is linked to higher MS incidence.
-
Near-infrared light from the sun may directly stimulate brain mitochondria, potentially supporting brain health and function.
Final Takeaway
This study provides compelling evidence that pulse high-dose vitamin D may reduce new MS-related brain lesions in patients with early signs of the disease. While more research is needed to confirm benefits on clinical symptoms and long-term outcomes, these findings support considering vitamin D as a potential add-on therapy—with careful medical supervision.
Note: High-dose vitamin D supplementation should always be managed by a physician, as excessive intake can lead to serious side effects such as hypercalcemia.
LINKS / REFERENCES: ECG / EKG Interpretation Explained Clearly (MedCram) | https://www.medcram.com/courses/ekg-e…
High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis (JAMA) | https://jamanetwork.com/journals/jama…
Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis (Journal of neurology, neurosurgery, and psychiatry) | https://pubmed.ncbi.nlm.nih.gov/23385…
Melatonin and the Optics of the Human Body (Melatonin Research) | https://www.melatonin-research.net/in…
MS Brain Scans (Wikimedia) | https://upload.wikimedia.org/wikipedi…